Literature DB >> 8376417

Influence of mouse apolipoprotein A-II on plasma lipoproteins in transgenic mice.

C C Hedrick1, L W Castellani, C H Warden, D L Puppione, A J Lusis.   

Abstract

The role of apolipoprotein A-II (apoA-II) in the metabolism of high density lipoproteins (HDL) is poorly understood. Previous studies of naturally occurring variations of apoA-II in mice have, however, suggested that apoA-II expression influences HDL size and concentration. We now provide definitive evidence of this using transgenic mice overexpressing mouse apoA-II. Thus, as compared with nontransgenic littermates, transgenic mice possessing 4-fold elevations of apoA-II mRNA and 2-3-fold elevations in plasma apoA-II levels exhibited more than a 2-fold increase in HDL levels as well as about a 25% increase in average HDL diameter. Overexpression of mouse apoA-II also resulted in a substantial decrease in the levels of apolipoprotein E associated with HDL, suggesting that apoA-II can displace apoE from HDL. The apoA-II transgenic mice also exhibited a 2-4-fold increase in plasma very low density and low density lipoprotein-cholesterol levels, suggesting novel interactions among the classes of plasma lipoproteins.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8376417

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  56 in total

1.  Naturally occurring variant of mouse apolipoprotein A-I alters the lipid and HDL association properties of the protein.

Authors:  Timothy J Sontag; Ronald Carnemolla; Tomas Vaisar; Catherine A Reardon; Godfrey S Getz
Journal:  J Lipid Res       Date:  2012-03-08       Impact factor: 5.922

2.  A biochemical fluorometric method for assessing the oxidative properties of HDL.

Authors:  Theodoros Kelesidis; Judith S Currier; Diana Huynh; David Meriwether; Christina Charles-Schoeman; Srinivasa T Reddy; Alan M Fogelman; Mohamad Navab; Otto O Yang
Journal:  J Lipid Res       Date:  2011-09-27       Impact factor: 5.922

3.  Systems genetics of susceptibility to obesity-induced diabetes in mice.

Authors:  Richard C Davis; Atila van Nas; Lawrence W Castellani; Yi Zhao; Zhiqiang Zhou; Pingzi Wen; Suzanne Yu; Hongxiu Qi; Melenie Rosales; Eric E Schadt; Karl W Broman; Miklós Péterfy; Aldons J Lusis
Journal:  Physiol Genomics       Date:  2011-10-18       Impact factor: 3.107

4.  Genetic control of high density lipoprotein-cholesterol in AcB/BcA recombinant congenic strains of mice.

Authors:  Sean A Wiltshire; Eduardo Diez; Qianqian Miao; Marie-Pierre Dubé; Mireille Gagné; Olivier Paquette; Ronald G Lafrenière; Momar Ndao; Lawrence W Castellani; Emil Skamene; Silvia M Vidal; Anny Fortin
Journal:  Physiol Genomics       Date:  2012-07-17       Impact factor: 3.107

5.  Testosterone inhibits early atherogenesis by conversion to estradiol: critical role of aromatase.

Authors:  L Nathan; W Shi; H Dinh; T K Mukherjee; X Wang; A J Lusis; G Chaudhuri
Journal:  Proc Natl Acad Sci U S A       Date:  2001-03-06       Impact factor: 11.205

6.  Reduced aortic lesions and elevated high density lipoprotein levels in transgenic mice overexpressing mouse apolipoprotein A-IV.

Authors:  R D Cohen; L W Castellani; J H Qiao; B J Van Lenten; A J Lusis; K Reue
Journal:  J Clin Invest       Date:  1997-04-15       Impact factor: 14.808

7.  Posttranslational modifications of apolipoprotein A-II proteoforms in type 2 diabetes.

Authors:  Ida Azizkhanian; Olgica Trenchevska; Yara Bashawri; Jiaqi Hu; Juraj Koska; Peter D Reaven; Randall W Nelson; Dobrin Nedelkov; Hussein N Yassine
Journal:  J Clin Lipidol       Date:  2016-03-08       Impact factor: 4.766

8.  Comparison of the structural and functional effects of monomeric and dimeric human apolipoprotein A-II in high density lipoprotein particles.

Authors:  S Lund-Katz; Y M Murley; E Yon; K L Gillotte; W S Davidson
Journal:  Lipids       Date:  1996-11       Impact factor: 1.880

9.  Apolipoprotein AII is a regulator of very low density lipoprotein metabolism and insulin resistance.

Authors:  Lawrence W Castellani; Cara N Nguyen; Sarada Charugundla; Michael M Weinstein; Chau X Doan; William S Blaner; Nuttaporn Wongsiriroj; Aldons J Lusis
Journal:  J Biol Chem       Date:  2007-12-26       Impact factor: 5.157

10.  Genetic disruption of myostatin reduces the development of proatherogenic dyslipidemia and atherogenic lesions in Ldlr null mice.

Authors:  Powen Tu; Shalender Bhasin; Paul W Hruz; Karen L Herbst; Lawrence W Castellani; Ning Hua; James A Hamilton; Wen Guo
Journal:  Diabetes       Date:  2009-06-09       Impact factor: 9.461

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.